Table 3.
Catalog of EQ-5D Utilities by Stage and Treatment Category
| Stage at Diagnosis /Treatment Category | N | Mean EQ-5D Utility (SD) | Median EQ-5D Utility (IQR) |
|---|---|---|---|
|
| |||
| Stage I | 750 | 0.81 (0.17) | 0.83 (0.23) |
| Surgery | 449 | 0.82 (0.16) | 0.83 (0.23) |
| Lobectomy | 244 | 0.83 (0.16) | 0.83 (0.22) |
| Wedge Resection | 48 | 0.79 (0.15) | 0.80 (0.15) |
| Pneumonectomy | 40 | 0.75 (0.18) | 0.80 (0.25) |
| Other Primary | 42 | 0.84 (0.13) | 0.82 (0.22) |
| Chemotherapy | 17 | 0.75 (0.23) | 0.82 (0.28) |
| Surgery w/Chemotherapy | 113 | 0.81 (0.14) | 0.82 (0.09) |
| Platinum | 41 | 0.79 (0.18) | 0.82 (0.11) |
| Non-Platinum* | 52 | 0.81 (0.11) | 0.82 (0.08) |
| Surgery w/Chemoradiotherapy | 30 | 0.84 (0.13) | 0.83 (0.23) |
| Platinum | 18 | 0.86 (0.12) | 0.84 (0.22) |
| Chest Radiation | 37 | 0.76 (0.20) | 0.82 (0.17) |
| Chemoradiotherapy | 32 | 0.76 (0.23) | 0.82 (0.22) |
| Platinum | 17 | 0.77 (0.26) | 0.82 (0.29) |
| No Treatment | 37 | 0.81 (0.19) | 0.82 (0.24) |
|
| |||
| Stage II | 232 | 0.77 (0.17) | 0.81 (0.14) |
| Surgery | 56 | 0.80 (0.15) | 0.83 (0.08) |
| Lobectomy | 29 | 0.80 (0.16) | 0.82 (0.06) |
| Surgery w/Chemotherapy | 61 | 0.76 (0.18) | 0.81 (0.14) |
| Platinum | 26 | 0.75 (0.18) | 0.81 (0.12) |
| Non-Platinum | 21 | 0.78 (0.20) | 0.81 (0.09) |
| Surgery w/Chemoradiotherapy | 42 | 0.76 (0.18) | 0.79 (0.15) |
| Platinum* | 27 | 0.74 (0.21) | 0.80 (0.28) |
| Non-Platinum* | 12 | 0.79 (0.14) | 0.81 (0.09) |
| Radiotherapy | 13 | 0.72 (0.19) | 0.80 (0.25) |
| Chemoradiotherapy | 28 | 0.78 (0.18) | 0.77 (0.41) |
| Platinum | 16 | 0.81 (0.16) | 0.82 (0.29) |
| No Treatment | 15 | 0.73 (0.14) | 0.75 (0.25) |
|
| |||
| Stage III | 649 | 0.77 (0.18) | 0.82 (0.15) |
| Surgery | 31 | 0.79 (0.17) | 0.82 (0.29) |
| Lobectomy | 14 | 0.78 (0.18) | 0.84 (0.18) |
| Chemotherapy | 93 | 0.78 (0.17) | 0.83 (0.15) |
| Platinum‡ | 29 | 0.78 (0.20) | 0.79 (0.24) |
| Non-platinum§ | 23 | 0.82 (0.14) | 0.83 (0.29) |
| Surgery w/Chemotherapy | 48 | 0.76 (0.15) | 0.80 (0.12) |
| Platinum | 13 | 0.72 (0.19) | 0.79 (0.14) |
| Non-Platinum* | 19 | 0.77 (0.15) | 0.82 (0.14) |
| Surgery w/Chemoradiotherapy | 94 | 0.75 (0.18) | 0.80 (0.14) |
| Platinum† | 41 | 0.72 (0.19) | 0.82 (0.15) |
| Non-Platinum* | 34 | 0.76 (0.18) | 0.77 (0.14) |
| Radiotherapy | 34 | 0.80 (0.14) | 0.83 (0.15) |
| Chemoradiotherapy | 308 | 0.78 (0.18) | 0.82 (0.15) |
| Platinum† | 175 | 0.77 (0.20) | 0.82 (0.09) |
| Non-Platinum† | 95 | 0.79 (0.16) | 0.83 (0.08) |
| No Treatment | 26 | 0.81 (0.17) | 0.82 (0.08) |
|
| |||
| Stage IV | 628 | 0.76 (0.19) | 0.82 (0.15) |
| Surgery | 17 | 0.69 (0.25) | 0.71 (0.41) |
| Chemotherapy | 214 | 0.79 (0.19) | 0.82 (0.09) |
| Platinum† | 78 | 0.79 (0.17) | 0.83 (0.08) |
| Non-platinum‡ | 67 | 0.77 (0.21) | 0.82 (0.10) |
| Surgery w/Chemotherapy | 33 | 0.80 (0.19) | 0.83 (0.23) |
| Platinum‡ | 19 | 0.84 (0.16) | 0.83 (0.19) |
| Surgery w/Chemoradiotherapy | 29 | 0.74 (0.22) | 0.82 (0.25) |
| Non-Platinum† | 13 | 0.80 (0.13) | 0.82 (0.08) |
| Chest Radiation | 29 | 0.72 (0.20) | 0.80 (0.14) |
| Chemoradiotherapy | 270 | 0.75 (0.18) | 0.79 (0.16) |
| Platinum* | 149 | 0.76 (0.17) | 0.80 (0.15) |
| Non-Platinum† | 82 | 0.75 (0.19) | 0.78 (0.14) |
| No Treatment | 33 | 0.79 (0.17) | 0.83 (0.10) |
*
5-10% patients also received targeted therapy
†
10-15% patients also received targeted therapy
‡
20-25% patients also received targeted therapy
§
35% patients also received targeted therapy